Science: A strong antibody combination with potential for the treatment of COVID-19 has been found.

, June 19, 2020 /--- PRNewswire/-- In a new study, researcher
s from research institutions such as the University of Maryland School of Medicine evaluated several human antibodies to determine the most effective combination and use it as a promising antiviral therapy to fight THE new coronavirus SARS-CoV-2 that causes COVID-19The study demonstrated the process of rapidly isolating, testing, and large-scale production of antibody drugs for any infectious disease using plasma from genetically engineered mice and patients with recovering COVID-19The findings were published online June 15, 2020 in the journal Science with the title "Research in human shuman smandscent humans data a SARS-CoV-2 antibody cocktail"picture from NIAID-RMLthe antibody combination assessed by these researchers will be used to treat patients with COVID-19 in aclinical triallaunched in early JuneThe study was funded by Regeneron, a biotech company based in Tully, N.Yantibodies are proteins that the immune system naturally produces against foreign invaders such as viruses andbacteriaAntibody therapy was first tried at the end of the 19th century, when scientists used serum extracted from the blood of infected animals to treat diphtheriain order to produce so-called monoclonal antibodies in an antibody combination used against COVID-19, the researchers first need to determine which antibodies are most effective against the new coronavirusthis involves determining which antibodies are most effectively bound to the stinging protein found on the surface of SARS-CoV-2The researchers evaluated thousands of human antibodies in plasma donated by recovered COVID-19 patientsThey also used genetically modified mice to produce human antibodies when infected with the virus "The ability to quickly acquire antibodies using both methods allows us to screen the antibodies we choose against live viruses to determine which antibodies have the strongest antiviral effects," said Matthew Frieman, co-author of the paper and an associate professor in the Department of Microbiology and Immuno
logy at the University of Maryland School of Medicine "He's been studying the coronavirus for the past 16 years, and since February he's been studying SARS-CoV-2 in his own safety lab Dr Frieman and his colleagues evaluated four of the most effective antibodies to determine the potential of each antibody to neutralise the SARS-CoV-2 virus They identified the most powerful combination of the two antibodies when used together "An important goal of this study is to evaluate the strongest antibodies that bind to different molecules in the stingprotein seislud protein so that they can be mixed together as a treatment," said Dr Stuart Weston, co-author of the paper and a postdoctoral fellow in the
Department of Microbiology and Immunology at the University of Maryland School of Medicine "
currently, antibody combinations containing these two antibodies are being tested in a new clinical trial sponsored by Regeneron, which clinical trials
will explore whether this antibody therapy can improve the prognosis of COVID-19 patients (inpatients and non-inpatients) It will also be tested as a preventive therapy in people who are at high risk of developing the disease but working in a healthcare environment or having come into contact with an infected person "Researchers at our medical school continue to provide important progress on all fronts to help fight the COVID-19 pandemic and ultimately save lives," said Professor E Albert Reece, dean of the University of Maryland School of Medicine at This particular study will not only help to develop potential new therapies for COVID-19, but may also have wider implications for the development of monoclonal antibody therapies for other diseases "(Bio Valley Bioon.com) References: Johanna Hansen et al Studies in human human symice and convalescent humans yield a SARS-CoV-2 antibody cocktail Science, 2020, doi: 10.1126/science.abd0827.
.